Acute hemodynamic changes during far infrared treatment of the arteriovenous fistula in hemodialysis patients

September 1, 2023

Abstract

Background: The arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis (HD) treatment and

preservation of a stable vascular access is crucial. Long term Far Infrared Radiation (FIR) has been found to increase

access flow together with an enhanced maturation and patency of the AVF. The acute effects of FIR on access flow have

been sparsely described and the results are contradictory, perhaps due to differences in measurement conditions and

other factors of importance for access flow.

Methods: Twenty patients in HD with an AVF were included. Each patient was randomized to receive either FIR

(FIR group) or no FIR (control group). The acute changes in access flow were investigated in both groups on the

second dialysis day of the week and during the first 1.5 h of the dialysis session. Concomitant changes in hemodynamic

parameters of importance for access flow were also explored.

Results: There was no significant change in access flow in the FIR group compared with the control group (median

(Interquartile Range)) (−10 (−413.8; 21.3) ml/min vs −17.5 (−83.8; 76.3) ml/min, p = 0.58). There was no significant

difference in any of the hemodynamic parameters between the FIR and the control group; cardiac output (−0.7 (−1.2;

−0.2) l/min vs −0.4 (−0.9; 0.1) l/min, p = 0.58), cardiac index (−0.3 (−0.5; −0.1)) l/min/m2 vs −0.3 (−0.4; 0) l/min/m2, p = 0.68),

mean arterial pressure (5.5 (−1.8; 8.4) mmHg vs 1.5 (−3; 6.3) mmHg, p = 0.35) and total peripheral resistance (2 (1.8; 3.4)

mmHg × min/l vs 1 (−0.3; 3.1) mmHg × min/l, p = 0.12).

Conclusion: In this trial, with a highly standardized set-up, one session of FIR did not result in any acute changes in

access flow. This was not due to differences in the hemodynamic parameters between the groups.

-J Vasc Access. 2023 Jul;24(4):739-746.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
July 16, 2025
FIRAPY Medical Japan proudly participated in the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , held in Osaka from June 27 to 29, 2025 . This year marked a major milestone for FIRAPY in Japan: a total of 11 FIRAPY-related research presentations were featured during the congress—showcasing growing academic interest in far-infrared therapy as a supportive, non-invasive treatment in dialysis care. represents a significant milestone in FIRAPY’s ongoing academic engagement in dialysis-related research.
FIRAPY collaborates with Taipei Veterans General Hospital in research on non-invasive therapies for
July 2, 2025
FIRAPY and Taipei Veterans General Hospital co-published a study in JFMA showing improved cardiovascular and infection outcomes in peritoneal dialysis patients using far-infrared therapy.
More Posts